Table 1.
Baseline characteristics of the study population
| Group 1 (aspirin 300 mg) | Group 2 (aspirin 75 mg) | Group 3 (clopidogrel) | Group 4 (placebo) | |
|---|---|---|---|---|
| Gender (n) | 4 male | 3 male | 5 male | 6 male |
| 11 female | 12 female | 10 female | 9 female | |
| Age (years) | 32.00 (30.00–35.25) | 33.50 (28.75–41.25) | 36.00 (31.5–43.50) | 37.00 (31.00–43.50) |
| SBP/DBP (mmHg) | 117 ± 4/78 ± 2 | 121 ± 5/82 ± 3 | 123 ± 4/84 ± 2 | 125 ± 6/81 ± 4 |
| Smokers (current) (n) | 2 | 3 | 2 | 1 |
| BMI (kg/m2) | 22.78 (20.81–26.00) | 25.23 (21.87–28.47) | 25.12 (20.61–28.42) | 23.63 (21.83–28.66) |
| HDL cholesterol (mmol/L) | 1.872 ± 0.08 | 1.751 ± 0.10 | 1.735 ± 0.09 | 1.793 ± 0.09 |
| LDL cholesterol (mmol/L) | 2.74 (2.42–3.33) | 2.87 (2.43–3.43) | 2.49 (2.24–3.15) | 2.20 (1.77–3.03) |
| Triglycerides (mmol/L) | 1.08 (0.72–1.32) | 1.00 (0.80–1.39) | 1.07 (0.81–1.50) | 0.93 (0.69–2.04) |
| Leucocytes (cells × 109/L) | 5.99 ± 0.31 | 6.01 ± 0.33 | 6.13 ± 0.38 | 6.23 ± 0.27 |
| Monocytes (cells × 109/L) | 0.5 (0.4–0.5) | 0.5 (0.4–0.5) | 0.4 (0.3–0.5) | 0.5 (0.4–0.625) |
| Platelets (×109/L) | 219.5 (190.3–240.8) | 211.0 (184.0–240.0) | 228.0 (204.0–251.0) | 219.5 (171.3–248.8) |
| HbA1c (mmol/mol) | 32.50 (30.75–36.00) | 32.00 (29.75–34.00) | 33.00 (31.00–34.00) | 34 (31.00–36.00) |
| Creatinine (mmol/L) | 73.53 ± 2.72 | 70.07 ± 3.27 | 72.79 ± 3.17 | 73.10 ± 3.54 |
Values are expressed as the mean ± SEM or median (IQR).
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.